Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results

Showing results for

The Oxford Vaccine Group is an independent multi-disciplinary clinical trials and epidemiology group based at the Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford. OVG works towards the goal of developing new and improved vaccines for the prevention of infection in adults and children.

Parental motivations, facilitators, and barriers to participating in a pediatric vaccine trial in Kathmandu, Nepal: A qualitative study.

Firth C. et al, (2026), Hum Vaccin Immunother, 22

The CCR2 inflammatory pathway is a target for improving severe disease and pulmonary inflammation in experimental COVID-19.

Kazungu Y. et al, (2026), Virulence, 17

Developing a global framework to assess a country's readiness and resilience to introduce a new vaccine or improve uptake of an underutilized vaccine.

Monk V. et al, (2026), Expert Rev Vaccines, 25

What is unhealthy about public health? Vaccination, evidence and the politics of uncertainty

Mezza M. and Vanderslott S., (2026), Humanities and Social Sciences Communications, 13

COVID-19 vaccine effectiveness and SARS-CoV-2 variants in Nepal: Test-negative case-control study and genetic sequencing (COVVAR Nepal)

Pokhrel B. et al, (2026), Vaccine X, 31

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.

Ebrahimi N. et al, (2026), Vaccine, 88

Age distribution of typhoid fever, paratyphoid fever, and non-typhoidal Salmonella invasive disease: a secondary analysis of global epidemiologic data

Batool R. et al, (2026)

Protection Against Recurrent Typhoid Fever Conferred by a Prior Episode: Evidence from a Large Cohort Study in Dhaka, Bangladesh.

Khanam F. et al, (2026), Clin Infect Dis

Genomic Epidemiology of Multi-Modal ESBL Gene Transmission among Enterobacterales in a Neonatal Unit

Parker MJ. et al, (2026)

A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case-control study.

O'Hagan S. et al, (2026), Lancet Child Adolesc Health

Moralized, Marginalized and Sanitized: How Stigma Shapes STI Vaccination Development, Policy and Uptake

Firth C. and Hodgson SH., (2026), Journal of the International AIDS Society, 29

Structural and immunogenic characterisation of ChAdOx1 Chik-derived Chikungunya VLPs supports a mechanistic rationale for vaccine-induced protection.

Kim YC. et al, (2026), Npj Viruses

Encephalitic Alphaviruses: Epidemiology, Pathogenesis and Vaccine Development.

Kisra N. et al, (2026), Vaccines (Basel), 14

Studying Early Life Live-Attenuated influenza virus immune Responses (STELLAR): study protocol for an exploratory observational study of the nasal mucosal and systemic immune response in healthy children given an intranasal live-attenuated influenza vaccine.

Kelleher K. et al, (2026), BMJ Open, 16

Innate immunity associates with protection from pneumococcal colonisation, but colonisation does not confer capsule-independent protection

Connor V. et al, (2026)

Effects of acute ebselen add-on treatment on resting state function connectivity in depressed patients with inadequate response to antidepressants.

Ramli FF. et al, (2026), Sci Rep

Automated virtual reality therapy to treat needle fears (trypanophobia) in adolescents in England: a proof-of-concept cohort study and a Phase II randomised controlled trial

FREEMAN D., (2026), EClinicalMedicine

Serological thresholds of risk reduction for infant group B streptococcus disease

Cantrell L. et al, (2026)

Critical Path to First-in-Human Batches of ChAdOx Vectors, Including for Emergency Response.

Peralta Alvarez MP. et al, (2026), Vaccines (Basel), 14

Increasing participation in cervical cancer screening.

Papenburg J. et al, (2026), BMJ, 393

Load More